Targeting the RNA m⁶A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Acute myeloid leukemia (AML) is a severe blood cancer originating from hematopoietic stem cells (HSCs).
• Leukemic stem cells (LSCs) are crucial for AML initiation and persistence.
• The role of RNA modifications, like N6-methyladenosine (m6A), in AML is an emerging area of research.

Purpose of the Study:

• To investigate the role of the m6A reader protein YTHDF2 in acute myeloid leukemia.
• To determine if YTHDF2 is a potential therapeutic target for AML.

Main Methods:

• Analysis of YTHDF2 expression in human AML samples.
• Functional studies using mouse and human AML models.
• Assessment of YTHDF2's impact on LSC and HSC function.

Main Results:

• YTHDF2 is overexpressed across various human AML subtypes.
• YTHDF2 is essential for AML initiation and propagation.
• YTHDF2 regulates the stability of m6A-modified transcripts critical for LSC function, including TNFRSF2.
• YTHDF2 deficiency leads to LSC apoptosis and enhances normal HSC activity.

Conclusions:

• YTHDF2 is a key driver of AML pathogenesis.
• Targeting YTHDF2 represents a promising therapeutic strategy for AML.
• YTHDF2 inhibition offers a selective approach to eliminate LSCs while preserving or enhancing HSCs.